IVABRADINE IN PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION: NEW DATA FROM THE SHIFT MULTICENTER RANDOMIZED TRIAL

IVABRADINE IN PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION: NEW DATA FROM THE SHIFT MULTICENTER RANDOMIZED TRIAL

Resting heart rate is a strong predictor of mortality and cardiovascular outcome in patients with chronic heart failure. А specific inhibitor of the If current in the sinoatrial node ivabradine improves clinical outcome in patients with heart failure and systolic dysfunction with heart rate ≥70 b.p....

Full description

Saved in:

Bibliographic Details
Main Authors:	S. N. Tereshchenko, I. V. Zirov, N. V. Romanova
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2016-08-01
Series:	Российский кардиологический журнал
Subjects:	heart failure ivabradine heart rate
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/891
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ivabradine therapy and correction of the target organ pathology in patients with ischemic chronic heart failure
by: M. V. Surovtseva, et al.
Published: (2013-06-01)

EFFICACY OF IVABRADINE AND VERAPAMIL IN PATIENTS WITH DIASTOLIC HEART FAILURE CAUSED BY LEFT VENTRICLE IMPAIRED RELAXATION
by: K. G. Adamyan, et al.
Published: (2016-01-01)

DYNAMICS OF HEART RATE VARIABILITY AND VENTRICULAR ECTOPIC ACTIVITY IN IVABRADINE-TREATED PATIENTS WITH CHRONIC HEART FAILURE
by: M. V. Surovtseva, et al.
Published: (2012-12-01)

The myocardial remodeling at ischemic chronic heart failure: the features of Ivabradine influence in experimental model
by: S. V. Fedorov, et al.
Published: (2016-12-01)

IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION
by: Yu. M. Lopatin
Published: (2012-08-01)

Successful treatment with ivabradine in a β‐blocker‐refractory patient with acute decompensated heart failure with reduced ejection fraction
by: Tomoko Inoue, et al.
Published: (2023-03-01)

Selective If-channel inhibitor ivabradine in the treatment of sinus tachycardia in coronary heart disease patients with acute heart failure and inferior myocardial infarction
by: S. A. Sayganov, et al.
Published: (2010-06-01)

Ivabradine in patients with heart failure: a systematic literature review
by: Zeba M. Khan, et al.
Published: (2023-12-01)

ASSESSMENT OF THE CHANGES IN BLOOD PRESSURE CIRCADIAN PROFILE AND VARIABILITY IN PATIENTS WITH CHRONIC HEART FAILURE AND ARTERIAL HYPERTENSION DURING COMBINED THERAPY INCLUDING IVABRADINE
by: M. V. Surovtseva, et al.
Published: (2015-12-01)

Ivabradine therapy effectiveness in patients with chronic heart failure, Functional Class III
by: S. G. Kanorskiy, et al.
Published: (2011-04-01)

Heart rate-reducing agents ivabradine and beta-adrenoblockers in the management of patients with stable effort angina
by: Z. M. Galeeva, et al.
Published: (2011-02-01)

Ivabradine – a new agent for coronary heart disease treatment
by: O. A. Maneshina, et al.
Published: (2006-06-01)

HEART RATE-LOWERING THERAPY IN THE TREATMENT OF CHRONIC HEART FAILURE
by: S. V. Shalaev, et al.
Published: (2015-09-01)

IVABRADINE THERAPY IN PATIENTS WITH CORONARY HEART DISEASE AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE
by: N. A. Zheleznyakova, et al.
Published: (2012-02-01)

The effect of ivabradine as part of standard therapy on vascular endothelial function and cardiac electrical instability in patients with post-infarction cardiosclerosis and heart failure
by: A. A. Abdullaev, et al.
Published: (2020-02-01)

Modern opportunities of heart rate regulation in coronary heart disease
by: N. Sh. Zagidullin, et al.
Published: (2013-10-01)

Heart rate-lowering therapy in gout patients with stable coronary artery disease: focus on ivabradine
by: N. N. Kushnarenko, et al.
Published: (2020-08-01)

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
by: Robert J.H. Miller, et al.
Published: (2022-06-01)

Practical aspects of vericiguat therapy in patients with heart failure with reduced ejection fraction. Expert council resolution
by: S. A. Boytsov, et al.
Published: (2023-05-01)

New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration
by: I. V. Gribkova
Published: (2024-03-01)

Characterizing Heart Failure Across the Spectrum of the Preserved Ejection Fraction: Does Heart Failure With Supranormal Ejection Fraction Exist? Data From the Swedish Heart Failure Registry
by: Laura Landucci, et al.
Published: (2025-03-01)

THE "NEW" DRUG CLASSES IN THE TREATMENT OF CHRONIC HEART FAILURE AND THEIR EVIDENCE BASE
by: S. N. Tereshchenko, et al.
Published: (2015-12-01)

Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction
by: Pushpraj Patel, et al.
Published: (2024-12-01)

IVABRADINE INFLUENCE ON SYSTOLIC AND DIASTOLIC FUNCTION OF HEART VENTRICLES IN PATIENTS WITH ISCHEMIC HEART DISEASE AFTER PRIMARY REVASCULARIZATION
by: N. V. Drobotya, et al.
Published: (2014-10-01)

Bioimpedance analysis predicts worsening events in outpatients with heart failure and reduced ejection fraction
by: Carlos Rodríguez‐López, et al.
Published: (2024-12-01)

Heart Failure with Preserved Ejection Fraction in Egypt: An Expert Opinion
by: Magdy Abdelhamid, et al.
Published: (2025-03-01)

Heart Failure with Perserved Ejection Fraction Current Diagnostic and Therapeutic Approaches
by: A. A. Shchendrygina, et al.
Published: (2021-07-01)

ROLE OF MEDICATIONS WITH NEGATIVE CHRONOTROPIC EFFECT IN THE TREATMENT OF PATIENTS WITH CORONARY HEART DISEASE AND HEART FAILURE
by: M. G. Glezer, et al.
Published: (2013-10-01)

Patient compliance and physicians’ adherence to guidelines on heart failure with reduced ejection fraction
by: V. N. Larina, et al.
Published: (2020-04-01)

Advanced heart failure with reduced ejection fraction at a young age: how long can we wait?
by: Arnold Péter Ráduly, et al.
Published: (2024-12-01)

Clinical management of heart failure with improved ejection fraction: treatment and maintenance
by: XU Tianyun, et al.
Published: (2025-04-01)

Heart failure with preserved left ventricular ejection fraction – clinical perspectives
by: Małgorzata Niemiec, et al.
Published: (2025-07-01)

Role of interleukins in heart failure with reduced ejection fraction
by: Oliwia Anna Segiet, et al.
Published: (2019-11-01)

New approach to heart rate control as mortality reduction method in cardiac patients: potential of a new If inhibitor, ivabradine
by: Yu. B. Belousov, et al.
Published: (2007-12-01)

Hepcidin and MELD-XI score as markers of multiple organ failure in patients with heart failure with preserved and reduced ejection fraction
by: V. I. Podzolkov, et al.
Published: (2020-07-01)

Prognostic Value of Epicardial Adipose Tissue in Heart Failure With Mid‐Range and Preserved Ejection Fraction: A Multicenter Study
by: Wenxian Wang, et al.
Published: (2024-12-01)

Echocardiographic characteristics of patients with ischemic and non-ischemic chronic heart failure with reduced ejection fraction
by: N. N. Ilov, et al.
Published: (2022-10-01)

Phenotypic clusters in heart failure with preserved and mid-range ejection fraction: new data and perspectives
by: O. V. Tsygankova, et al.
Published: (2021-05-01)

Predictors of adverse events in patients with ischemic chronic heart failure with reduced ejection fraction and renal dysfunction
by: D. A. Lashkul
Published: (2016-06-01)

COMPARATIVE ANALYSIS OF HOSPITAL PHARMACOTHERAPY OF CHRONIC HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTIONS IN 2009-2010 AND 2014-2015
by: O. V. Reshetko, et al.
Published: (2018-03-01)